AlloVir, Inc. (ALVR)の価格はいくらですか

AlloVir, Inc. (ALVR)の価格は$9.81です

AlloVir, Inc. (ALVR)の時価総額は何ですか

AlloVir, Inc. (ALVR)の時価総額は$48.68Mです

AlloVir, Inc.（ALVR）発行済株式数

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

年	発行済株式数	変化
2026 (TTM)	23.80M	379.57%
2024	4.96M	10.90%
2023	4.47M	35.75%
2022	3.30M	22.10%
2021	2.70M	133.42%
2020	1.16M	-36.07%
2019	1.81M	38.40%
2018	1.31M	0.00%

年

発行済株式数

変化

2026 (TTM)

23.80M

379.57%

2024

4.96M

10.90%

2023

4.47M

35.75%

2022

3.30M

22.10%

2021

2.70M

133.42%

2020

1.16M

-36.07%

2019

1.81M

38.40%

2018

1.31M

0.00%

企業	発行済株式数	差	国
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	966.93%	US
Argenx SE ARGX.US	62.19M	161.31%	NL
CSL Limited CSL.AX	483.58M	1,932.06%	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	396.00M	1,564.05%	US

企業

発行済株式数

差

国